Qvanteq’s bioactive stent surface
The bioactive Qstent is based on an easy to apply surface technology. This technology can be used with any stent platform.
The Qstent mode of action was established in extensive in-vitro studies and takes advantage of factors intrinsically available in the blood:
A physico-chemical treatment process creates a durable and ultra-hydrophilic stent surface (1). Upon introduction of the stent into the blood vessel, this surface selectively engages neutrophil-promoting proteins (2) directly from patient’s blood. These proteins subsequently start a cascade (3) & (4) that ultimately results in a controlled tissue response (5a & 5b) such as:
1) Increased speed of endothelialization
2) Reduced neointimal hyperplasia
Technological advantages of Qstent surface
Unlike other stent coated with e.g. drugs, antibodies, etc., no coating and no elution of active substances is required. This minimizes known risks associated with current surface coating technologies.
The Qstent technology has been applied to the leading commercial stent platforms, essentially with similar positive in-vivo outcome: studies conducted by CBSET (www.cbset.org) showed reduced neointimal hyperplasia and improved endothelialization compared to commercially available and untreated stents.
In-vitro studies showed significantly reduced platelet adhesion promising minimized thrombogenicity.